List of Excipients in Branded Drug DORZOLAMIDE HCL AND TIMOLOL MALEATE

« Back to Dashboard

Generic Drugs Containing DORZOLAMIDE HCL AND TIMOLOL MALEATE

Company	Ingredient	NDC	Excipient
Akorn	dorzolamide hydrochloride and timolol maleate	17478-514	BENZALKONIUM CHLORIDE
Akorn	dorzolamide hydrochloride and timolol maleate	17478-514	HYDROXYETHYL CELLULOSE
Akorn	dorzolamide hydrochloride and timolol maleate	17478-514	MANNITOL
Akorn	dorzolamide hydrochloride and timolol maleate	17478-514	SODIUM CITRATE

What are the Most Frequently-Used Excipients in DORZOLAMIDE HCL AND TIMOLOL MALEATE?

# Of NDCs	Excipient
2	BENZALKONIUM CHLORIDE
2	HYDROXYETHYL CELLULOSE
2	MANNITOL
2	SODIUM CITRATE

Excipient Strategy and Commercial Opportunities for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Products

Last updated: August 14, 2026

Dorzolamide hydrochloride and timolol maleate ophthalmic solution is a mature fixed-dose glaucoma combination with established generic competition. The strongest commercial opportunities are preservative-free delivery, improved multidose packaging, better ocular tolerability, manufacturing efficiency, and differentiated regulatory positioning rather than new chemical-entity exclusivity.

The reference product, Cosopt, combines dorzolamide hydrochloride 2% and timolol maleate 0.5% for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product is an aqueous ophthalmic solution and is available in preserved and preservative-free presentations in certain markets. FDA-approved generic versions compete primarily on price, supply reliability, bottle performance, and tolerability.

What is dorzolamide hydrochloride and timolol maleate ophthalmic solution?

Dorzolamide is a topical carbonic anhydrase inhibitor. Timolol is a topical beta-adrenergic receptor blocker. The combination reduces aqueous humor production through complementary pharmacologic mechanisms.

Attribute	Product characteristic
Active ingredients	Dorzolamide hydrochloride and timolol maleate
Strength	Dorzolamide 2% and timolol 0.5%
Dosage form	Sterile ophthalmic solution
Primary indication	Elevated intraocular pressure in open-angle glaucoma or ocular hypertension
Reference product	Cosopt
Regulatory pathway for generics	Abbreviated New Drug Application
Primary dosage-form risk	Preservative exposure, ocular irritation, bottle contamination, and dose consistency
Principal commercial differentiators	Preservative-free format, multidose delivery, price, supply, tolerability, and packaging

The formulation must maintain chemical stability for both active ingredients, preserve sterility throughout the labeled shelf life, control pH and osmolality, and deliver reproducible drop volume.

What excipients are used in dorzolamide and timolol ophthalmic products?

The core excipient system generally includes a buffering agent, tonicity modifier, viscosity-adjusting agent in some preserved products, pH adjusters, preservative where applicable, and purified water.

Typical preserved formulation

The conventional Cosopt formulation contains excipients associated with aqueous ophthalmic stability and antimicrobial preservation, including benzalkonium chloride, sodium citrate, mannitol, hydroxyethyl cellulose, sodium hydroxide, and water for injection or purified water, depending on the labeling jurisdiction and manufacturing specification. The precise qualitative and quantitative composition should be taken from the applicable approved product label and regulatory filing rather than inferred from a generic formula.[1]

Typical preservative-free formulation

Preservative-free products generally remove benzalkonium chloride and rely on single-use containers, unit-dose packaging, or specialized multidose systems. The formulation may retain sodium citrate, mannitol, sodium hydroxide, and water while adjusting container and fill-finish controls to maintain sterility.[2]

Excipient function	Candidate excipient class	Commercial purpose
Buffer	Citrate buffer	Controls pH and supports chemical stability
Tonicity agent	Mannitol, sodium chloride, or equivalent	Improves ocular comfort and osmolality control
Viscosity modifier	Hydroxyethyl cellulose or similar polymer	Supports residence time and drop behavior
Preservative	Benzalkonium chloride or alternative system	Controls microbial growth in multidose bottles
pH adjustment	Sodium hydroxide or acid	Brings the product into the target pH range
Vehicle	Sterile water	Dissolves and delivers the active ingredients
Chelator, where justified	EDTA or equivalent	May support preservative performance and metal-ion control

Excipients are not interchangeable solely on the basis of compendial status. Each substitution can affect pH, osmolality, viscosity, preservative efficacy, active-ingredient stability, extractables, leachables, and bioequivalence.

How should an excipient strategy be designed for this product?

A successful strategy should treat the formulation and container as one delivery system. The active ingredients are established, so the value lies in reducing formulation liabilities while preserving the reference product's clinical performance.

Preservative-free strategy

Preservative-free development is the clearest formulation opportunity. Benzalkonium chloride can cause ocular-surface irritation, especially with chronic use and in patients with dry eye, ocular-surface disease, or frequent exposure to multiple preserved ophthalmic products. Removing benzalkonium chloride can support positioning for chronic-use patients and specialists who favor preservative-free therapy.

The principal development burdens are:

• Sterility assurance over the full in-use period
• Container-closure integrity
• Drop-dose consistency
• Compatibility with low-shear or nontraditional dispensing systems
• Microbial ingress control
• Stability after opening
• Extractables and leachables
• Demonstration of comparable clinical performance

A unit-dose format simplifies microbial control but increases packaging cost, material consumption, shipping volume, and patient handling burden. A preservative-free multidose bottle can improve convenience and reduce waste, but its valve, closure, and air-management system can create more complex device and regulatory work.

Lower-irritation preserved strategy

A preserved formulation remains commercially relevant where cost, pharmacy handling, and multidose convenience dominate. The strategy can focus on reducing preservative concentration, using an alternative preservative system, or improving the interaction between benzalkonium chloride and the container.

This approach requires evidence that the alternative system maintains antimicrobial effectiveness without creating new ocular tolerability or compatibility problems. Preservative efficacy testing should be integrated with stability studies rather than treated as a late-stage release test.[3]

Viscosity and drop-size strategy

Hydroxyethyl cellulose or another viscosity modifier can affect ocular residence time, drop size, blinking sensation, and patient acceptance. Higher viscosity may improve retention but can cause blurred vision or a sticky sensation. It can also alter bottle performance and dose uniformity.

A commercially useful target is a viscosity range that preserves handling characteristics close to the reference product while minimizing transient visual disturbance. Drop size should be measured across bottle orientation, fill level, temperature, and user actuation force.

Buffer and osmolality strategy

Citrate buffering can support pH control, but the buffer concentration must be balanced against ocular tolerability and active-ingredient stability. Dorzolamide hydrochloride and timolol maleate have different chemical properties, so the formulation must be optimized for the combination rather than for either active ingredient separately.

Osmolality close to the tear film is generally preferred for comfort, but exact matching is not always necessary if the formulation remains clinically tolerable. Excessive tonicity adjustment can create its own tolerability issue.

What formulations are protected by patents or regulatory exclusivity?

The original Cosopt chemical and combination-product exclusivity has expired. The current competitive environment is primarily governed by formulation know-how, container technology, manufacturing controls, trademarks, and any surviving jurisdiction-specific patents rather than by new chemical-entity exclusivity.

Protection category	Current commercial relevance
Dorzolamide composition patents	Expired for the mature marketed product
Timolol composition patents	Expired
Basic fixed-dose combination protection	Historical protection; original exclusivity has expired
Preserved ophthalmic formulation claims	May have historical or jurisdiction-specific relevance
Preservative-free formulation claims	Potentially relevant where tied to a specific concentration, packaging system, or stability profile
Multidose dispensing technology	Can create device and combination-product protection
Manufacturing process claims	May protect impurity control, sterilization, filling, or stability outcomes
Method-of-use claims	May cover dosing, patient subsets, or treatment combinations in certain jurisdictions
Trademarks and trade dress	Commercially relevant after patent expiry

An applicant should distinguish between an excipient patent, a container patent, and a patent claiming the full drug-device combination. A broad claim to a conventional aqueous solution is generally more vulnerable than a claim tied to a specific preservative-free system, drop-control mechanism, or stability profile.

What is the FDA regulatory status and Orange Book position?

Cosopt was approved by FDA as an NDA product, and generic dorzolamide hydrochloride and timolol maleate ophthalmic solutions have entered through the ANDA pathway. FDA lists approved products and patent or exclusivity information in Drugs@FDA and the Orange Book.[4][5]

The relevant regulatory points are:

1. The product is a small-molecule ophthalmic combination, not a biologic.
2. Biosimilar approval is not the applicable pathway.
3. Generic competitors generally rely on ANDA approval and must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements.
4. A new formulation, preservative-free presentation, or container system may require a new drug application, a supplement, or an ANDA strategy depending on the extent of the change and the reference product relied upon.
5. Patents and exclusivity must be checked against the specific NDA and dosage-form presentation, including preserved and preservative-free products.

The Orange Book should be reviewed separately for the original preserved product and any preservative-free reference product. A product may have different listed patents, labeling, and regulatory histories depending on its NDA and presentation.

When did dorzolamide and timolol lose exclusivity?

The original product has been commercially mature for many years. Its five-year new chemical entity exclusivity and any ordinary three-year approval exclusivity periods are no longer barriers to generic entry. The market has already demonstrated generic substitution.

Current entry risk is therefore less likely to come from basic active-ingredient patents and more likely to involve:

• A listed formulation patent
• A method-of-use patent
• A container or dispensing-device patent
• A regulatory distinction between preserved and preservative-free products
• Manufacturing capacity and sterile-product quality
• State-level substitution and contracting requirements

Which companies are challenging the reference product?

Generic competition has historically included major ophthalmic and generic manufacturers such as Sandoz, Mylan, Teva, Akorn, and other ANDA sponsors, depending on the market and product presentation. The competitive field changes through acquisitions, divestitures, discontinuations, and supply events.

A current company-by-company Paragraph IV assessment cannot be inferred from historical approvals. FDA approval records, Orange Book entries, court dockets, and ANDA litigation notices must be read together because an approved generic may have entered after a patent certification, settlement, or non-infringing position.

What Paragraph IV and litigation risks exist?

Paragraph IV risk is highest when a new applicant seeks an ANDA approval while an Orange Book-listed patent remains active. For this mature combination, the principal litigation questions are:

• Whether any patent remains listed against the relied-upon reference product
• Whether the applicant made a Paragraph IV certification
• Whether the patent covers the proposed preservative system or container
• Whether a 30-month stay was triggered
• Whether the parties reached a license or launch-date settlement
• Whether the patent was delisted, expired, or invalidated

A formulation developer should conduct a claim chart against active patents before committing to a formulation that copies a protected excipient ratio, preservative system, or device configuration. A design-around using different buffer concentration, viscosity modifier, container technology, or unit-dose architecture may reduce litigation exposure.

How strong is the patent estate for dorzolamide and timolol?

The estate is commercially weaker at the active-ingredient level and potentially stronger at the delivery-system level.

Estate component	Relative strength
Active ingredients	Low, because the ingredients are long genericized
Fixed-dose combination	Low to moderate, depending on jurisdiction and claim status
Conventional aqueous excipients	Low unless tied to a narrow stability or performance limitation
Preservative-free formulation	Moderate where supported by unexpected stability, tolerability, or shelf-life data
Multidose device	Moderate to strong if the device prevents contamination and has enforceable claims
Sterile manufacturing process	Moderate, but enforcement can be difficult without access to manufacturing evidence
Method of use	Variable; patient-selection and dosing claims may be narrow
Trade secrets	Potentially strong for process parameters, but not publicly enforceable like patents

The most defensible intellectual property strategy combines composition claims with device claims, process claims, and data supporting a clinically meaningful product advantage.

What commercial opportunities exist beyond a standard generic?

Preservative-free chronic-use product

A preservative-free version can target patients with ocular-surface disease, long-term therapy, intolerance to benzalkonium chloride, or exposure to several topical glaucoma medications. The value proposition is strongest when supported by tolerability data and a convenient dispensing system.

Premium multidose bottle

A contamination-resistant multidose bottle can reduce unit-dose waste and improve adherence. Commercial success depends on reliable actuation, low residual volume, simple patient handling, and a competitive price.

Contract manufacturing and private-label supply

Sterile ophthalmic manufacturing capacity is constrained relative to ordinary oral-solid-dose manufacturing. A reliable supplier can create opportunities through private-label agreements, regional licensing, hospital contracts, and supply arrangements with ophthalmology-focused companies.

Emerging-market access

Markets with high generic substitution and limited access to branded glaucoma products may support a low-cost formulation. The key requirements are stable supply, robust packaging, climatic-zone stability, and regulatory documentation for multiple jurisdictions.

Combination-product line extensions

A manufacturer with a glaucoma portfolio can use the product as an anchor for adjacent products, including separate dorzolamide and timolol products, prostaglandin combinations, preservative-free products, and bottle technologies shared across ophthalmic SKUs.

How does dorzolamide and timolol compare with competing glaucoma products?

Product category	Commercial advantage	Main limitation
Dorzolamide/timolol	Established efficacy and generic price	Preservative and dosing tolerability concerns
Timolol monotherapy	Low cost and simple formulation	Less intensive pressure reduction for some patients
Dorzolamide monotherapy	Useful when beta-blockers are unsuitable	More frequent dosing and local irritation
Prostaglandin analogs	Strong efficacy and once-daily use	Higher cost and cosmetic or ocular-surface effects
Brimonidine/timolol	Alternative fixed combination	Allergy and central nervous system tolerability concerns
Preservative-free glaucoma products	Ocular-surface differentiation	Higher packaging and manufacturing cost

The combination remains commercially relevant because it can reduce bottle burden and improve adherence compared with separate active ingredients. Its main competitive weakness is that it is often dosed twice daily and may contain a preservative.

What generic launch scenarios are most likely?

Low-price standard generic

This approach uses a conventional preserved bottle, established excipients, and high-volume manufacturing. It has the lowest development risk but faces intense price competition and limited differentiation.

Preservative-free premium generic

This approach supports higher pricing and specialist prescribing but requires stronger packaging, sterility, stability, and patient-use data. It also faces a smaller but more valuable target segment.

Device-led launch

A differentiated bottle can support branding, licensing, or co-development even when the active formulation is generic. Device performance must be protected through patents, trade secrets, or regulatory complexity.

Regional licensing launch

A company may license a finished product or technology to regional ophthalmology distributors. This reduces direct commercial infrastructure requirements but shifts value toward manufacturing reliability and regulatory transferability.

What manufacturing and intellectual-property barriers matter most?

Sterile ophthalmic production is the principal operational barrier. The manufacturer must control bioburden, endotoxin, particulate matter, container closure, fill volume, and aseptic process performance. Any excipient change can affect filtration, adsorption, viscosity, and filling behavior.

The most valuable manufacturing know-how may include:

• Order of excipient addition
• pH adjustment sequence
• Active-ingredient dissolution conditions
• Filtration compatibility
• Hold-time controls
• Container sterilization
• Low-volume fill accuracy
• In-use microbial protection
• Extractables and leachables control

These parameters may be protectable as trade secrets even when the finished formulation is difficult to patent broadly.

Key Takeaways

• Dorzolamide hydrochloride 2% and timolol maleate 0.5% is a mature generic ophthalmic combination.
• The basic active-ingredient and original combination exclusivity barriers have expired.
• Preservative-free delivery is the strongest formulation opportunity.
• The main commercial value lies in ocular tolerability, multidose packaging, supply reliability, and manufacturing quality.
• BAK-free or low-preservative strategies require integrated formulation, container, sterility, and in-use stability development.
• Biosimilar risk is not relevant because this is a small-molecule drug.
• Paragraph IV and litigation risk depends on current Orange Book listings for the specific reference product and presentation.
• A defensible IP position is more likely to arise from container technology, formulation performance, manufacturing processes, or narrow method-of-use claims than from the active ingredients.
• Standard generic launches face severe price pressure. Preservative-free and device-led products offer better margin potential.
• Sterile ophthalmic manufacturing capacity is a material barrier to entry and a licensing opportunity.

FAQs

Is benzalkonium chloride necessary in dorzolamide and timolol eye drops?

No. Benzalkonium chloride is used in many multidose preserved ophthalmic products, but preservative-free presentations can use unit-dose packaging or specialized multidose systems.

Can a company patent a new dorzolamide/timolol excipient combination?

Yes, but patent strength depends on novelty, non-obviousness, enablement, and evidence of a specific technical advantage. A conventional buffer or tonicity adjustment alone is unlikely to provide strong protection.

Is preservative-free dorzolamide/timolol eligible for an ANDA?

The pathway depends on the reference product, formulation differences, labeling, and FDA's determination of pharmaceutical equivalence and bioequivalence. A materially different presentation may require a different regulatory strategy.

What patient segment is most attractive for a preservative-free product?

Patients with chronic glaucoma treatment, ocular-surface disease, dry eye, preservative intolerance, or exposure to several preserved ophthalmic medications are the clearest target segment.

Can dorzolamide/timolol be sold as a biosimilar?

No. Dorzolamide hydrochloride and timolol maleate are small-molecule active ingredients. The relevant generic pathway is generally an ANDA, not a biosimilar application.

References

1. U.S. Food and Drug Administration. (2024). Cosopt prescribing information: Dorzolamide hydrochloride and timolol maleate ophthalmic solution. FDA.

2. National Library of Medicine. (2024). DailyMed: Dorzolamide hydrochloride and timolol maleate ophthalmic solution. DailyMed.

3. United States Pharmacopeia. (2024). General chapter <51>: Antimicrobial effectiveness testing. USP-NF.

4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

6. U.S. Food and Drug Administration. (2016). Ophthalmic drug products for topical delivery: Guidance for industry. FDA.